The complete series
A closer look
starts here.
Questions about the science and the service deserve separate, careful answers.
Best GLP-1 providers, with the product question kept in view
A ten-option access review that separates the care company, medicine and purchase agreement.
Read the explainer ↗What “dual incretin” means—and what it leaves unanswered
Two receptor targets describe how a medicine acts. They do not give a patient a treatment ranking.
Read the explainer ↗How to read a head-to-head tirzepatide study
A result becomes more useful when the population, comparator and limits travel with it.
Read the explainer ↗Ingredient, brand and preparation: three labels to keep separate
A familiar ingredient name cannot do all the work of identifying the medicine in an offer.
Read the explainer ↗The trial population belongs in the headline
A result becomes more useful when the people studied remain visible beside the percentage.
Read the explainer ↗Seventy-two weeks is a study horizon, not a lifetime promise
Separate the time a result was measured from the time a treatment may be used.
Read the explainer ↗Dual action does not mean two prescriptions
Receptor activity describes how a medicine acts; it is not a recipe for combining treatments.
Read the explainer ↗STEP Semaglutide Analysis: Digestive Symptoms, Duration, and Weight Loss
A post hoc analysis separates symptom frequency, event duration and treatment discontinuation from the question of whether gastrointestinal discomfort drives semaglutide’s weight effects.
Read the explainer ↗Tirzepatide Weight Loss Without Nausea: What the SURMOUNT Symptom Analysis Shows
A post hoc analysis of four trials found substantial weight reduction with and without nausea, vomiting, or diarrhea. The strongest inference is about symptom necessity—not which incretin receptor caused the results.
Read the explainer ↗